'Leclaza (Lazertinib)', a Korean anticancer drug developed by Yuhan, is conducting a Sponsor Initiated Clinical Trial for patients with non-small cell lung cancer Leptomeningeal metastasis.

Since the competitive drug Tagrisso (Osimertinib, AZ) has proven effective in metastasis to the central nervous system such as brain and soft meninges, if this test of Leclaza is successful, it is expected to be competitive in the 3rd generation EGFR-TKI market. The MFDS approved Leclaza's Sponsor Initiated Clinical Trial plan submitted by Seoul National University Hospital on the 5th.

This trial is a phase II clinical trial in which Lazertinib and Pemetrexed Disodium Heptahydrate (Alimta) are